Boston Scientific Corporation
BSX
$95.12
-$0.13-0.14%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 4.56B | 4.21B | 4.12B | 3.86B | 3.73B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.56B | 4.21B | 4.12B | 3.86B | 3.73B |
| Cost of Revenue | 1.48B | 1.32B | 1.28B | 1.22B | 1.16B |
| Gross Profit | 3.09B | 2.89B | 2.84B | 2.64B | 2.57B |
| SG&A Expenses | 1.61B | 1.56B | 1.45B | 1.36B | 1.38B |
| Depreciation & Amortization | 225.00M | 205.00M | 213.00M | 214.00M | 208.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.77B | 3.49B | 3.32B | 3.16B | 3.11B |
| Operating Income | 790.00M | 718.00M | 799.00M | 693.00M | 617.00M |
| Income Before Tax | 585.00M | 669.00M | 420.00M | 608.00M | 505.00M |
| Income Tax Expenses | 23.00M | 200.00M | 98.00M | 115.00M | 1.00M |
| Earnings from Continuing Operations | 562.00M | 469.00M | 322.00M | 493.00M | 504.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 4.00M | -- | 2.00M | 1.00M | 1.00M |
| Net Income | 566.00M | 469.00M | 324.00M | 494.00M | 505.00M |
| EBIT | 790.00M | 718.00M | 799.00M | 693.00M | 617.00M |
| EBITDA | 1.14B | 1.02B | 1.11B | 997.00M | 930.00M |
| EPS Basic | 0.38 | 0.32 | 0.22 | 0.34 | 0.34 |
| Normalized Basic EPS | 0.32 | 0.28 | 0.31 | 0.26 | 0.25 |
| EPS Diluted | 0.38 | 0.32 | 0.22 | 0.33 | 0.34 |
| Normalized Diluted EPS | 0.32 | 0.27 | 0.31 | 0.26 | 0.24 |
| Average Basic Shares Outstanding | 1.47B | 1.47B | 1.47B | 1.47B | 1.47B |
| Average Diluted Shares Outstanding | 1.49B | 1.49B | 1.48B | 1.48B | 1.48B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | 0.00% |